AbbVie delivered a third-quarter beat and raised full-year profit guidance, driven by continued momentum in immunology and neuroscience franchises. The company reported $17.4 billion in sales and $3.82 in EPS, both above consensus, and lifted its full-year EPS outlook. CEO Rob Michael said AbbVie has capacity for additional acquisitions but prefers bolt-on transactions over another megadeal after the company’s 2020 Allergan purchase. Immunology franchise sales were $9.17 billion, with Skyrizi rising 23% year over year and management raising its 2025 sales projection again. In neuroscience, AbbVie pointed to 19% year-over-year growth to $3.4 billion in Q3 and highlighted Vraylar reaching more than $1 billion in global sales. The guidance raises the bar for continued execution into 2027 as the market watches durability across franchise renewals.